Substantial decline in hospital admissions for heart failure accompanied by increased community mortality during COVID-19 pandemic. by Shoaib, A et al.
1 
 
Substantial decline in hospital admissions for heart failure accompanied by increased 
community mortality during COVID-19 pandemic. 
 
Ahmad Shoaib1, Harriette GC Van Spall2,3,4, Jianhua Wu5,6, John GF Cleland7 Theresa A 
McDonagh8, Muhammad Rashid1, Mohamed O Mohamed1, Fozia Z Ahmed9, John 
Deanfield10, Mark de Belder11, Chris P Gale5,6,12, Mamas A Mamas1 
1. Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary 
Care and Health Sciences, Keele University, United Kingdom (UK) 
2. Department of Medicine, Department of Health Research Methods, Evidence, and Impact, 
McMaster University, Hamilton, Canada 
3. Population Health Research Institute, Hamilton, Canada 
4. ICES, McMaster University, Hamilton, Canada 
5. Leeds Institute for Data Analytics, University of Leeds, Leeds, UK 
6. Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK  
7. Robertson Centre for Biostatistics, University of Glasgow, UK 
8. School of Cardiovascular Medicine, Kings College, London, UK 
9. Department of Cardiology, Manchester University Hospitals NHS trust, Manchester, UK  
10. Institute of Cardiovascular Sciences, University College London, London, UK 
11. National Institute for Cardiovascular Outcomes Research, Barts Health NHS Trust, 
London, UK 
12. Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK 
Corresponding author: 
Dr Ahmad Shoaib 
Keele Cardiovascular Research Group, Centre for Prognosis Research 
Keele University, Stoke-on-Trent, UK 
E-mail: drahmadshoaib@yahoo.com 
Tel: +44 1782 671654  Fax: +44 1782 734719 
Word count: 2,963 
Key words: Heart failure, Acute heart failure, COVID-19, Hospitalisation, Mortality 
 
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, 






/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab040/6287062 by guest on 09 June 2021
2 
 











Objective: We hypothesised that a decline in admissions with heart failure during COVID-19 
pandemic would lead to a reciprocal rise in mortality for patients with heart failure in the 
community. 
Methods: We used national heart failure audit data to identify 36,974 adults who had a hospital 
admission with a primary diagnosis of heart failure between February and May in either 2018, 
2019 or 2020.  
Results: Hospital admissions for heart failure in 2018/19 averaged 160/day but were much 
lower in 2020, reaching a nadir of 64/day on 27th March-2020 (incidence rate ratio:0.40, 95% 
CI:0.38-0.42). The proportion discharged on guideline-recommended pharmacotherapies was 
similar in 2018/19 compared to the same period in 2020. Between 1st February-2020 and 31st 
May-2020, there was a 29% decrease in hospital deaths related to heart failure (IRR:0.71,95% 
CI:0.67-0.75; estimated decline of 448 deaths), a 31% increase in heart failure deaths at home 
(IRR:1.31,95% CI:1.24-1.39; estimated excess 539) and a 28% increase in heart failure deaths 
in care homes and hospices (IRR:1.28,95% CI:1.18-1.40; estimated excess 189). All-cause, in-
patient death was similar in the COVID-19 and pre-COVID-19 periods (OR:1.02,95% CI: 
0.94–1.10). After hospital discharge, 30-day mortality was higher in 2020 compared to 2018/19 
(OR:1.57, 95% CI:1.38–1.78).  
Conclusion: Compared with the rolling daily average in 2018/19, there was a substantial 
decline in admissions for heart failure but an increase in deaths from heart failure in the 
community. Despite similar rates of prescription of guideline-recommended therapy, mortality 











What is already known about this subject? 
A decline in admission for many cardiovascular diseases was observed during first wave of 
COVID-19 pandemic 
What does this study add?  
The reduction in heart failure (HF) admissions during the COVID-19 pandemic was 
accompanied by an increase in heart failure deaths in the community and 30-days after 
discharge. 
How might this impact on clinical practice  
Novel models of care at home and in the community should be explored for patients with HF 
during the COVID-19 pandemic, with public health messages towards this group of patients 











Health care systems across the globe were restructured during the COVID-19 pandemic 
in anticipation of a large influx of emergency admissions. This reconfiguration resulted in 
closure of elective and out-patient services, reductions in speciality beds and the relocation of 
cardiology staff to other high-dependency areas of the hospital.1, 2 Such measures may have 
affected both the provision of healthcare to patients with heart failure as well as their outcomes.  
During the early and peak phases of the first wave of the COVID-19 pandemic, 
hospitals in the United Kingdom (UK) described a decline in admissions for many 
cardiovascular conditions, including HF.3, 4 These reports are limited because they are either 
based on the activity of a small number of centres, lack granularity about treatments and 
processes of care, or do not report outcomes following hospital discharge.5  
We hypothesised that a decline in admissions with heart failure would lead to a 
reciprocal rise in mortality for patients with heart failure in the community. England has a suite 
of clinical and administrative datasets that routinely collect detailed health information and 
outcomes for the population. We used such multi-sourced and linked electronic heath records 
from the National Heart Failure Audit (NHFA), Hospital Episode Statistics (HES) and the Civil 
Registration of Death Data of the Office for National Statistics (ONS) to quantify the extent 
and impact of changes in admissions for heart failure and understand whether in-hospital 
management of patients and their post discharge outcomes has been affected as a result of the 












The current study was based on English data from three national databases: NHFA, 
HES and the Civil Registration of Deaths, ONS (Supplement Figures 1-2). The first confirmed 
case of coronavirus in England was on 29th January 2020; thus, we took 1st February 2020 as 
the start date of the COVID-19 period. 
 
The National Heart Failure Audit  
The NHFA was established in 2007 for hospitals in England & Wales to monitor & 
improve the quality of care of patients admitted to hospital with a diagnosis of heart failure, 
capturing information on their clinical presentation, characteristics, investigations, specialist 
input, management and outcomes in the real world 6, 7. Further details about NHFA is presented 
in Supplement method section.  For the purpose of this analysis, we included data relating to 
an admission with a diagnosis of heart failure from 1st January 2018 to 31st May 2020 from 
England. We dichotomised study participants on the basis of their date of index hospitalization: 
COVID-19 period (1st February – 31st May 2020) and Pre-COVID-19 period (1st February - 
31st May 2018 and 1st February – 31st May 2019). Furthermore, we excluded hospitals that did 
not submit data consistently each month during this period. We only included the first 
admission for heart failure during the whole study period (a patient could potentially be 
hospitalised more than once). Records with missing data for sex and National Health Service 
(NHS) identification number were excluded.  
 
Hospital Episode Statistics 
HES collects data for all hospital admissions, outpatient appointments and accident and 
emergency attendances for all NHS hospitals in England. HES data was extracted for the same 
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International Classification of Diseases (ICD)-10 recorded in the primary position. HES data 
are more complete, since they included patients from hospitals not include in the above NHFA 
dataset, and were used to calculate the daily rate of admissions for heart failure.  
 
Civil Registration of Death 
The Civil Registration of Deaths, ONS dataset comprises mortality information for all deaths 
in England. Deaths certification and registration is a legal requirement in the UK and a doctor 
who has seen the deceased during the last 14 days of life must complete a medical certificate 
of causes of death (MCCD) within 5 days unless a post-mortem examination or inquest is 
organised. During the COVID-19 pandemic, emergency guidance enabled any doctor in the 
UK (not just the attending) to complete the medical certificate of cause of death, the duration 
of time over which the deceased was not seen before referral to the coroner was extended from 
14 to 28 days and causes of death could be ‘to the best of their knowledge and belief’ without 
diagnostic proof, if appropriate and to avoid delay. ICD-10 codes, corresponding to the 
principal and contributory causes of death on the MCCD, were used to identify deaths from 
heart failure. Individual patient data from the NHFA were linked using each patient’s unique 
NHS identification number to the ONS dataset to track mortality for 30 days from hospital 
discharge; this also allowed mortality within 30-days of admission to be calculated. We also 
collected ONS data for all adult deaths in England. We reported daily deaths for heart failure 
recorded in the primary position and in any position. 
 
Rationale for using Multiple databases 
Each dataset utilized in this study has its own strengths and limitations and only a combination 
of datasets or linkage analysis can give a comprehensive overview of the impact of COVID-
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the NHFA dataset is the national HF dataset that was used to describe clinical characteristics, 
pharmacotherapy and mortality during index admission and its linkage with ONS dataset 
provided further information about mortality during 30-day after admission and cause of death. 
The NHFA captures approximately 70% of total HF admissions captured in HES, which is an 
administrative dataset of all hospital admissions in the UK that we used to describe the overall 
rate of hospitalizations for heart failure. However, HES as an administrative dataset, lacks 
granular details around processes of care, and treatments of HF. Therefore we used a 
combination of these two databases, to better define clinical pathways, treatments, admission 
rates and outcomes.  
 
Outcomes 
The main outcomes of interest were in-hospital all-cause mortality, 30-day all-cause mortality 
(measuring from the date of hospital admission), and the daily incidence of heart failure-related 
deaths by place of death up until the 14th July 2020.  
 
Statistical methods  
Daily admissions and deaths from heart failure were depicted using a 7-day simple moving 
average (the mean number of daily deaths for that day and the preceding 6 days) from 1st 
February to 31st May of each year. Poisson regression was used to estimate the incidence rate 
ratio (IRR) of daily deaths related to heart failure during the pre-COVID-19 and COVID-19 
periods, adjusted for time trends by including a cubic spline function of time. We calculated 
the excess deaths by subtracting the observed total deaths from March 2020 to the average total 
deaths in 2018 and 2019 in the same period.  
Continuous data were presented as medians with interquartile ranges (IQR), and categorical 
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using the Chi-squared test for non-parametric data, Student’s T test for normally distributed 
continuous variables and Wilcoxon rank sum test where continuous data were not normally 
distributed. 
For the NHFA, we used multiple imputation with chained equations to impute data for all 
variables with missing information. Multivariable logistic regression models were fit to 
estimate the risk of death for the COVID-19 and pre-COVID-19 periods. In a sensitivity 
analysis, we repeated the multivariable logistic regression analysis for 30-day mortality 
amongst patients discharged alive during each period (Supplement method section for more 
details). 
Analyses were performed using the Stata/MP 16.1 statistical software (College Station, TX) 




All datasets used in our study collect information routinely used for audit research purposes 
without requiring informed patient consent fall under section 251 of the NHS Act 2006 and 
therefore institutional board review was not required for this study.8, 9 The UK Secretary of 
State for Health and Social Care has released a time limited Notice, under Regulation 3(4) of 
the NHS (Control of Patient Information Regulations) 2002, to analyse confidential patient 
information. This study is a part of work stream authorised by the Scientific Advisory Group 
for Emergencies (SAGE), the body accountable for ensuring that appropriate and coordinated 
scientific advice is made available to UK government decision makers. SAGE helps UK cross- 
government decisions in the Cabinet Office Briefing Room and by NHS England, which 
supervises commissioning decisions in the NHS, and NHS Improvement, which is responsible 











Admissions with heart failure 
There were 36,974 index events available from the NHFA, of which 27,183 (74%) 
occurred in pre-COVID-19 years and 9,791 (26%) during the COVID-19 period 
(Supplementary Figure 1 & 2). In the HES record, the total number of index admissions for 
heart failure was 38,470 and 14,150 for the same three time-periods.  
There was a decline in daily admissions for heart failure (NHFA: from 112 to 60 per 
day: IRR: 0.53, 95% CI: 0.52-0.55) (HES: from 157 to 92 per day; IRR: 0.60, 95% CI: 0.59-
0.62) from the middle of March 2020 compared with daily admissions in the same period in 
2018/2019. Thereafter, there was a persistently low rate of admissions as compared with 
similar months during the pre-COVID-19 period (Figure 1). These trends were similar across 
age groups, sex, and heart failure categories (Supplement Figures 3 & 4). There were similar 
distributions of ages, sex and heart failure categories in patient cohorts admitted during the 
COVID-19 and pre-COVID-19 periods (Table 1). The prevalence of a prior history of 
hypertension, diabetes mellitus, valvular heart disease (VHD), asthma, chronic obstructive 
pulmonary disease (COPD) and cerebrovascular accident (CVA) were similar. Patients 
admitted during the COVID-19 period had higher plasma concentrations of brain natriuretic 
peptide (BNP) or N-terminal Brain Natriuretic Peptide (NT-Pro BNP) and a similar prevalence 
of AF and HFrEF relative to those admitted during the pre-COVID-19 era (Table 1). 
Prescription of pharmacotherapy were broadly similar between the two cohorts (Table 1). The 
median length of hospital stay was 7 days (IQR 3-13) during the COVID-19 period and 8 days 
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Location and number of deaths (HF as a cause of death at primary position).  
The numbers of deaths reported by ONS with heart failure as the primary cause were 
6,900, 6,739 and 7,187, between February and May in 2018, 2019 and 2020 respectively.  
We observed an increase in deaths due to heart failure from middle of March to late April 2020 
in the COVID-19 period compared with the pre-COVID period (Figure 2). There was a 29% 
decline in deaths related to heart failure in hospital (IRR: 0.71, 95% CI:  0.67 - 0.75, equivalent 
to a decrease of 448 deaths), a 31% increase in deaths at home (IRR: 1.31, 95% CI: 1.24-1.39, 
equivalent to an increase of 539 deaths) and a 28% increase in deaths in care homes and 
hospices (IRR: 1.28, 95% CI: 1.18-1.40, equivalent to an increase of 189 deaths). In total, we 
estimate an excess of 280 deaths from heart failure during the COVID-19 study period.  
 
Mortality in patients admitted with heart failure captured by the NHFA 
Inpatient deaths. All-cause, in-patient mortality was similar in the COVID-19 and pre-
COVID-19 periods (10% in both groups, OR:1.02, 95% CI: 0.94 – 1.10) (Table 2).   
30-day deaths. Mortality within 30-days from admission was higher in the COVID-19 
versus pre-COVID-19 period (15% vs. 13%, OR: 1.15, 95% CI: 1.07 – 1.23) (Table 2). A lower 
proportion of patients in the COVID-19 versus pre-COVID-19 period had heart failure as a 
principal cause of death on the death certificate (48.3% vs 53.3%) and a greater proportion, as 
expected, had COVID-19 as a principal cause of death (9.6% vs 0) (Table 3 and Supplement 
figure 5).  
          Increasing age, longer QRS duration, worse NYHA class and increasing peripheral 
oedema were independently associated with increased risk of death in hospital in both study 
periods, whereas prior history of DM was independently associated with increased risk of death 
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Sensitivity analysis. Death at 30-days from admission was higher for patients who 
discharged alive from hospital during the COVID-19 versus pre-COVID-19 period (OR: 1.57, 
95% CI: 1.38- 1.78)) (Supplement Table 1) and multivariable analysis revealed similar 
predictors of 30-day mortality (Supplement Table 2). Details about missing data in all variables 
by study cohort are presented in Supplement table 3.  
Figure 3 is our central illustration figure and visual take home graphics.  
 
Discussion 
In this analysis of national multi-sourced electronic health records, we examined the 
impact of the COVID-19 pandemic on heart failure hospitalizations and deaths in England. We 
observed a steady decline in heart failure hospitalizations from the middle of March 2020, with 
reductions ranging from 40% (HES) to 47% (NHFA); this was followed by persistently low 
rates of hospitalisation during the COVID-19 period relative to the same months in the pre-
COVID-19 period. Despite the restructuring of hospital services and diversion of resources to 
COVID-19 care, adjusted in-hospital mortality related to heart failure and provision of 
guideline-directed heart failure medications and investigations were similar in the COVID-19 
and pre-COVID-19 periods in NHFA. Finally, the reduction in heart failure admissions during 
the COVID-19 pandemic was accompanied by an increase in heart failure deaths in the 
community, with 280 excess deaths with heart failure as a principal cause over the 4-month 
pandemic period. 
The NHFA is the largest heart failure registry in the world. It was established to monitor 
and report hospital clinical activity against a set of key performance indicators. The large 
sample size provides sufficient statistical power to capture differences in clinical outcomes 
between the patient groups studied. This is the first national analysis to assess the direct and 
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with heart failure in the hospital and community. We found a dramatic decline in heart failure 
hospitalizations during the COVID-19 pandemic. This reduction probably reflects successful 
attempts at hospital avoidance by patients to minimise the risk of hospital-acquired COVID-
19 and, perhaps, increased support in the community. Patients with heart failure may have 
remained at home due to fears of exposure to COVID-19, breaking their shielding or social 
quarantine, leading to an increase in heart failure deaths in the community. Furthermore, some 
NHS trusts introduced new rapid access cardiology clinics and use of acute care services at 
home to reduced hospitalizations during COVID-19 pandemic but its impact on overall NHS 
service is relatively unknown. 10-12. In addition, hospital services were reconfigured to create 
additional beds for COVID-19 patients by repurposing cardiology wards, cancelling out-
patient clinics (or replacing them with remote clinics) and postponing elective procedural 
activities.  
Our work suggests that the quality of care for patients hospitalized for heart failure was 
not compromised despite the structural and organizational changes during the COVID-19 
pandemic. The rates of investigations, including echocardiography, were similar in the 
COVID-19 and pre-COVID-19 periods. Plasma concentrations of BNP/NT-proBNP were 
somewhat higher in the COVID-19 period, suggesting a higher threshold for admission and 
sicker patients. Simultaneously, it appears that these "sicker" patients received on average less 
aggressive diuresis (less median weight loss during hospitalization) during the hospitalization 
and had shorter length of stay. Interestingly we observed an increased odds of 30-day mortality 
during the COVID period that may be explained by our observation that sicker patients were 
less aggressively diuresed and had shorter lengths of stay. patients may have been discharged 
prematurely to create more hospital beds or with arrangements to receive palliation for some 
end stage heart failure patients in community. Gaps in post-discharge care due to closure of 
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care and increased risk of death following hospitalization. These are the possible main factors 
for observing higher natriuretic peptides values, shorter stay in the hospital and lesser weight 
loss during COVID-19 period compared to Pre-COVID-19 period. Meanwhile, deaths 
attributed to heart failure in the community and care homes also increased during the COVID-
19 pandemic. 
A recent analysis of patients hospitalized with heart failure in Denmark did not report 
an increase in in-patient deaths during the COVID-19 period relative to a similar period in 2019 
(142 vs 132 per 1000 person-year; age and sex adjusted death rate ratio, 1.05 (95% CI, 0.93 – 
1.18, P 0.45).5 In contrast, a study of 1,372 patients in two hospitals in London found that 
patients hospitalized for heart failure during the COVID-19 pandemic had worse outcomes (in-
hospital deaths) than those hospitalized during a similar period in 2019 (Hazard ratio; 2.23, 
95% CI 1.34 – 3.72, P = 0.002).3 Small sample size, lack of robust multivariable analyses and 
non-availability of outcome data after discharge were the main limitations of these studies 
which may yield different results compared to current study.  
 Similar to any observational study there are limitations. While we had information 
about the proportion of patients with HFrEF, we could not differentiate between patients who 
had heart failure with mid-range ejection fraction (HFmrEF) and HF with preserved ejection 
fraction (HFpEF). Some general aspects of health such as frailty, mood, social network and 
cognitive functions were not recorded. More detailed assessments of cardiac function, 
especially with echocardiography or other imaging modalities were not available. During the 
earlier phase of the COVID-19 pandemic, widespread COVID-19 testing was not available in 
England for everyone and was limited to targeted and high-risk patients. It’s not possible to 
ascertain from current study how many HF patients actually had COVID-19 infection during 
hospital admission. It’s also possible that some patients were admitted due to COVID-19 
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primary diagnosis for discharge or death was not HF. Other patients might have been admitted 
in hospital due to exacerbation of HF and became infected with COVID-19 during the hospital 
stay and ultimately died in the hospital or community. Finally, during the COVID-19 
pandemic, emergency guidance enabled any doctor in the UK to complete the medical 
certificate of cause of death and causes of death could be ‘to the best of their knowledge and 
belief’. This may have resulted in misclassification or bias towards certain causes of death. 
However if anything, this would tend to under-estimate HF deaths in the community that may 
have been labelled as COVID-19 deaths. Moreover, the accuracy of a diagnosis of heart failure 
on death certificates is uncertain. One study published in 2017 reported  that there was no prior 
record of heart failure in the primary or secondary care record for 55% of ONS records 
reporting heart failure as a cause of death.13 However, this limitation applied equally on both 
study cohorts.  
 
Conclusion 
This analysis of approximately 37,000 acute heart failure admissions is the first national 
study to compare incidence, processes of care, treatments, and clinical outcomes during and 
after hospitalisation during the COVID-19 pandemic. We report a 47% reduction in heart 
failure hospitalizations during the COVID-19 pandemic, accompanied by an increase in heart 
failure deaths at home and in care homes and hospices. We estimate 280 excess heart failure 
deaths during this period, and 2165 deaths excess deaths in patients with heart failure. Despite 
restructuring of hospital services during the COVID-19 pandemic, standard of care appears to 
have been maintained for those patients hospitalised with heart failure with similar adjusted in-
hospital mortality rates, but higher 30-day mortality rates compared to the Pre-COVID-19 
period. The reduction in heart failure hospitalization with concomitant increase in heart failure 
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peak COVID-19 pandemic; “stay at home, protect the NHS” should need to be elaborated 
further to the public that “stay at home” does not mean to avoid attending hospitals or seeking 
healthcare advice in the event of illness as it may influence clinical outcome”.14  
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Table 1: Baseline characteristics of patients admitted for heart failure during the Pre-
COVID-19 and COVID-19 periods (data derived from NHFA database)  
 
Variables  Pre-COVID-19 
period 
COVID-19 period p-value 
Number of patients 27,183 9,791  
Age, (IQR) 80 (71 – 87) 80 (71 – 87) 0.47 
Women (%) 11,925 (44%) 4,267 (44%) 0.62 
Race    
White  12,985 (76%) 4,769 (79%) <0.001 
BAME 4,046 (24%) 1,265 (21%) <0.001 
Location of in-patient care    
Cardiology 11,281 (42%) 3,871 (40%) 0.001 
General Medicine 9,091 (33%) 3,344 (34%) 
Geriatric Medicine  4,097 (15%) 1,477 (15%) 
Other 2,671 (10%) 1,071 (11%) 
NYHA Class at the time of hospitalization  
Class 1 1,550 (6%) 654 (7%) <0.001 
Class 2 4,007 (15%) 1,359 (14%) 
Class 3 11,957 (46%) 4,495 (48%) 
Class 4 8,525 (33%) 2,877 (31%) 
Peripheral oedema    
No oedema 5,535 (22%) 2,137 (23%) <0.001 
Mild oedema 6,185 (24%) 1,947 (21%) 
Moderate oedema 8,638 (34%) 3,150 (34%) 
Severe oedema 5,341 (21%) 1,951 (21%) 
Pre-existing co-morbid 
conditions 
   
CAD 10,917 (41%) 3,655 (39%) <0.001 
Valve disease 7,670 (29%) 2,667 (28%) 0.09 
Hypertension  14,991 (56%) 5,443 (56%) 0.35 
Diabetes mellitus 9,312 (35%) 3,263 (34%) 0.13 
Asthma 2,447 (9%) 917 (10%) 0.25 
COPD 2,812 (18%) 1,678 (18%) 0.23 
Prior device therapy    
CRT-D/CRT-P 1,256 (5%) 386 (4%) 0.09 
ICD 728 (3%) 267 (3%) 
PPM 2,490 (9%) 890 (9%) 
In-hospital clinical investigations 
Heart rate at admission 
(beat/minute) (IQR) 
83 (70 – 100) 84 (71 – 101) 0.002 
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Hemoglobin at discharge 
(grams/dl) (IQR) 
12 (10 -13) 12 (10 -13) 0.89 
Creatinine at discharge (mg /dl) 
(IQR)  
108 (83 – 148) 106 (82– 147) 0.01 
Serum Na at discharge (mmol/L) 
(IQR) 
138 (135 – 141) 138 (135 – 141) 0.77 
Plasma BNP during hospitalization 
(ng/L) (IQR) 
570 (82 – 1515) 761 (263 – 1927) <0.001 
Plasma NT-proBNP (ng/L) (IQR) 4,526  
(1,897 – 10,417) 
5,046  
(2,198 – 11,372) 
<0.001 
QRS interval (milliseconds) 106 (91 – 138) 106 (91 – 136) 0.67 
AF on ECG (%)  11,827 (47%) 4,305 (47%) 0.27 
HFrEF (%) 14,371 (53%) 5,101 (52%) 0.20 
Valve disease (%) 8,999 (33%) 3,208 (33%) 0.55 
Echocardiogram performed during 
hospitalization  
23,935 (88%) 8,513 (87%) 0.005 
Length of stay, pharmacotherapy at discharge and discharge planning 
Length of hospital stay (IQR) 8 (4 – 15) 7 (3 – 13) <0.001 
ACEi/ARB (%) 
 
12,738 (72%) 4,527 (74%) 0.001 
Beta blockers (%) 
 
17,219 (85%) 6,234 (87%) 0.001 
Loop diuretics (%) 21,747 (94%) 7,784 (94%) 0.65 
Thiazide diuretics (%)  911 (6%) 281 (5%) 0.39 
MRA (%) 8,348 (50%) 2,945 (53%) 0.001 
Digoxin (%) 
 
3,633 (21%) 1,269 (22%) 0.19 
Median weight loss during 
hospitalization (Kg) (IQR) 
-2.1 (-.5.7 to  0) -1.80 (-5.4 to 0)  0.001 
Heart failure nurse follow up (%) 13,923 (58%) 4,969 (57%) 0.46 
Cardiology follow up (%) 10,749 (45%) 3,615 (42%) <0.001 
 
NHFA; National Heart Failure Audit, IQR; Interquartile range, HF; Heart failure, BAME; 
Black, Asian & Minority ethnic, NYHA; New York Heart Association, CAD; Coronary artery 
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CRT; Cardiac resynchronization therapy, ICD; implanted cardiac defibrillator, PPM, 
Permanent pacemaker, BP; blood pressure, Na; Sodium, BNP; Brain Natriuretic Peptide, NT-
pro BNP; N-terminal pro type Brain Natriuretic Peptide, HFrEF; heart failure with reduced 
ejection fraction, HFpEF; heart failure with preserved ejection fraction, AF; atrial fibrillation, 
ECG; electrocardiogram, ACEi; angiotensin converting enzyme inhibitor, ARB; angiotensin 
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Table 2: Crude data & adjusted odds of in-patient and 30-day mortality from admission 
during the COVID-19 versus Pre-COVID-19 period (data derived from Civil 
Registration of Death and NHFA databases) 
 
 
Outcome Total Pre-COVID-19 period COVID-19 period P-Value 





3,752 2,752 (10%) 1,000 (10%) 0.80 
All cause 30-day 
mortality from date 
of admission (%) 
5,033 3,594 (13%) 1,439 (15%) <0.001 
Multivariable Logistic regression analysis on non-imputed data (complete case analysis) 
 
Outcome OR ⃰ Lower bound 95% CI Upper bound 95% 
CI 
P-value 
Inpatient mortality  
(n = 21,036) 
1.02 0.91 1.13 0.73 
30-day mortality 
from date of 
admission  
(n  = 21,036) 
1.17 1.07 1.29 0.001 
Multivariable Logistic regression analysis on imputed data 
 
Outcome OR ⃰ Lower bound 95% CI Upper bound 95% 
CI 
P-value 
Inpatient mortality  
(n  = 36,956) 
1.02 0.94 1.1 0.66 
30-day mortality 
from date of 
admission  
(n  = 36,956) 
1.15 
 
1.07 1.23 <0.001 
  
30-day outcomes were measured from date of hospital admission 
 
 Area under ROC curve: 0.52, SE: 0.005, 95% CI 0.52 – 0.53 
 
 Area under ROC curve: 0.79, SE: 0.003, 95% CI 0.78 – 0.80 
 
OR; odds ratio, NHFA; National Heart Failure Audit, ROC; receiver operator characteristics, 
SE; standard error, CI; confidence interval 
⃰ Adjusted for age, gender, prior medical conditions (Coronary artery disease, Valvular heart 
disease, Diabetes mellitus, hypertension, asthma, Chronic obstructive pulmonary disease), 
prior smoking history, place of care. atrial fibrillation on ECG, heart rate at hospitalization, 
blood pressure at hospitalization, QRS duration, New York Heart association class shortness 
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Table 3: Comparison of in-patient and 30-day from admission cause of death during Pre-

























Cardiac causes       






















































COVID-19 0 82  
(8.3%) 
- 0 136  
(9.6%) 
- 
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Table 4: Factors independently associated with in-hospital mortality during the Pre-





Variables  Pre-COVID-19 period COVID-19 period 
N= 27,172 9,784 
Model 
performance  
Area under ROC curve: 0.68,  
SE: 0.004, 95% CI: 0.67 – 0.69 
Area under ROC curve: 0.68,  
SE: 0.004, 95% CI: 0.67 – 0.69 
 Odds ratio 95% CI P-value Odds ratio 95% CI P-value 
Age  1.04 1.03 – 1.05 <0.001 1.03 1.02 – 1.04 <0.001 




1.03 1.02 – 1.04 0.02 1.01 0.99 – 1.02 0.09 
Admission BP 
(mmhg) 
0.93 0.92 – 0.94 <0.001 0.92 0.90-0.93 <0.001 
QRS duration  1.06 1.04 - 1.07 <0.001 1.04 1.01- 1.06 0.01 
CAD 0.98 0.90 – 1.07 0.69 0.99 0.86– 1.40 0.86 
Valve disease 1.13 1.03 – 1.22 0.01 1.03 0.88 – 1.22 0.73 
hypertension  0.88 0.81 – 0.95 0.002 0.76 0.66 – 0.87 <0.001 
DM 1.01 0.92 – 1.10 0.84 1.18 1.02 – 1.37 0.02 
asthma 0.73 0.64 – 0.86 <0.001 1.01 0.82 – 1.27 0.96 
COPD 1.26 1.22 – 1.65 0.003 0.98 0.82 – 1.18 0.88 
Atrial 
fibrillation 
1.02 0.93 – 1.12 0.63 0.90 0.77 – 1.05 0.20 
NYHA III/IV 1.17 1.05 – 1.31 0.006 1.27 1.05 – 1.52 0.01 
peripheral 
oedema 




0.72 0.65 – 0.78 <0.001 0.70 0.61 – 0.81 <0.001 
IECD 0.85 0.75 – 0.97 0.01 0.91 0.74– 1.11 0.35 
HFrEF 1.01 0.92 – 1.1 0.97 0.96 0.83 – 1.11 0.57 
 
ROC; receiver operator characteristics, SE; standard error, CI; confidence interval , HF; heart 
failure, NYHA; New York Heart Association, CAD; coronary artery disease, COPD; chronic 
obstructive pulmonary disease, , HFrEF; heart Failure with reduced ejection fraction,  ECG; 
electrocardiogram 
 (per 1 unit change in model) 
 NYHA class I/II are reference 
 None or mild peripheral oedema are reference 
 per 10 degree rise in blood pressure  
 per 10 millisecond change  
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Figure 1: Daily number of heart failure hospitalizations between 1st February and 31st May 2018, 




Legend: Each curve represents a 7-day rolling average of daily heart failure hospitalizations. 
A decline in daily admissions for heart failure (NHFA: from 112 to 60 per day: IRR: 0.53, 95% 
CI: 0.52-0.55); HES: from 157 to 92 per day; IRR: 0.60, 95% CI: 0.59-0.62) from the middle 
of March 2020. There was a persistently low rate of admissions as compared with similar 
months during the Pre-COVID-19 period 
 
NHFA; National Heart Failure Audit, HES; Hospital Episode Statistic 
Pre-COVID-19 period: February- May 2018 & February-May 2019 
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Figure 2: Comparison of daily deaths in hospital, home and care home/hospice during 







Legend: Each curve represents a 7-day rolling average of daily deaths. There was an increase 
in deaths due to heart failure from middle of March to late April 2020 in the Covid-19 period 
compared to pre-COVID-19 period. A 29% decline in deaths related to heart failure in hospital 
(IRR: 0.71, 95% CI:  0.67 - 0.75, equivalent to a decrease of 448 deaths), a 31% increase of 
deaths at home (IRR: 1.31, 95% CI: 1.24-1.39, equivalent to an increase of 539 deaths) and a 
28% increase in deaths in care homes and hospices (IRR: 1.28, 95% CI: 1.18-1.40, equivalent 
to an increase of 189 deaths) 
 
HF; heart failure, IRR; Incidence rate ratio 
Pre-COVI-19 period: February- May 2018 & February-May 2019 
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Legend: Graphical summary  
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